絞り込み

16644

広告

新型肺炎 外務省の渡航中止勧告受け日本企業が対応強化 (NHK)

外務省が日本人を対象に出している「感染症危険情報」のうち、湖北省全体の危険レベルを引き上げ、渡航の中止を勧告したことを受けて日本企業も対応を強化しています。 こ...

  1. [医学] 高蛋白質食はmTOR伝達を煽っ...
  2. 新型肺炎 中国 感染拡大防止へ厳戒態勢の...
  3. フィリピン 中国人観光客460人余送還へ...
  4. 原子力審議会議事録の言葉を分析 (デイリ...

ニュース一覧

「elotuzumab」の検索結果

255件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.

[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation].

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

A Novel Approach to Remove Interference of Therapeutic Monoclonal Antibody with Serum Protein Electrophoresis.

[Management of multiple myeloma in the relapsed/refractory patient].

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of NF-κB pathways.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります